WCM
ATNM icon

Westend Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Westend Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-33
Closed -$2K – 65
2015
Q2 		$2K Hold
33
– – ﹤0.01% 79
2015
Q1 		$3K Hold
33
– – ﹤0.01% 77
2014
Q4 		$6K Hold
33
– – 0.01% 96
2014
Q3 		$7K Buy
+33
New +$6.54K 0.01% 87

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Westend Capital Management's ATNM Position: Q3 2015 in Review

Westend Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q3 2015, closing a stake of 33 shares — an estimated $2K sold.

Westend Capital Management first reported a position in ATNM in Q3 2014 and held it in 4 quarters. The position peaked at $7K in Q3 2014. 27 funds tracked by Wall St. Rank hold ATNM as of Q3 2015.

  • Westend Capital Management reported no remaining Actinium Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Westend Capital Management sold 33 Actinium Pharmaceuticals shares in Q3 2015, an estimated $2K.
  • Westend Capital Management first reported a position in Actinium Pharmaceuticals in Q3 2014 and held it in 4 quarters.
  • Westend Capital Management's Actinium Pharmaceuticals position peaked at $7K in Q3 2014.
  • 27 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2015.

Based on Westend Capital Management's 13F filing for Q3 2015, filed 17 Nov 2015.